Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

ere observed. Two events of clinically asymptomatic Grade 3 QTc prolongation occurred in two of four patients enrolled at the 350 mg dose when read by machine. On manual re-read these events were determined to be Grade 2. The dose of 300 mg was declared to be the MTD when administered daily.

The adverse event profile in phase 2 was consistent with phase 1: the most common adverse events were Grade 1 and 2 diarrhea, rash, fatigue, and nausea. Clinically asymptomatic QTc prolongation was also observed.

About the Phase 2 Trial of XL647 as First-Line Therapy

This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. XL647 is administered orally at a dose of 350 mg on Days 1-5 of repeated 14-day cycles. The trial is designed to enrich for patients with activating mutations in the EGF receptor (EGFR) which have been associated with improved sensitivity to other EGFR inhibitors. Based on the selection criteria, Exelixis anticipates that approximately 30 percent of subjects in the trial will have activating EGFR mutations. This design should allow the accumulation of data for patients with and without EGFR mutations, helping to identify those patients most likely to benefit from treatment with XL647.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability, demonstrates excellent activity in target-specific cellular functional assays, and has shown sustained inhibition of target RTKs in vivo in preclinical models following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exe
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... , March 31, 2015 Ryan ... the board of directors of Hyperion Therapeutics, Inc. ("Hyperion" ... breaches of fiduciary duty and other violations of law ... to Horizon Pharma plc in a transaction valued at ... of Hyperion and would like to learn more about ...
(Date:3/31/2015)... Ill. , March 31, 2015 ... ® Motion™-15-Days and Invia ® Motion™-Endure ... portfolio of products and services. These new devices, ... reflect Medela,s continued commitment to provide innovative, high-quality ... advanced wound treatment to patients. "We ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. 2Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2
... SAN FRANCISCO, Jan. 16, 2012 Dicom Systems ( ... is pleased to announce their selection as the Vendor ... California-based full service physician-owned teleradiology group. ... you have the capacity to turn your current storage ...
... 2012 International medical technology company,  ...   Stockholm : SECT B) , announces ...   at Meharry. Sectra , s suite ... and orthopaedics will enable the hospital to automate workflow, ...
Cached Medicine Technology:ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2Sectra to Provide Suite of Integrated Radiology IT Solutions to Nashville General Hospital at Meharry 2Sectra to Provide Suite of Integrated Radiology IT Solutions to Nashville General Hospital at Meharry 3
(Date:3/31/2015)... Indianapolis, Indiana (PRWEB) March 31, 2015 ... Indiana statewide Network Service Provider, announces that Joink, ... mile transport providers. According to Cory Childs, ... wholesale data transport specifically targeted at Internet Service ... “Our fiber transport service provides Joink with diverse ...
(Date:3/31/2015)... CirugiaPlastica-Mexico.net , an exclusive plastic ... company, announced today an expansion of providers in ... most experienced and committed plastic surgeons in Mexico, ... elegant, life-altering cosmetic enhancements. Overall, a larger number ... in Mexico due to the improved technology, greater ...
(Date:3/31/2015)... 2015 For its fourth consecutive year, Survivor ... for cancer survivors, is hoping to raise thousands of ... Loyola Center for Fitness (LCF) in Maywood, IL. ... instructor for the LCF, Nicole Capone, launched the Survivor Spin ... teams participate in a fun-filled evening of friendly indoor cycling ...
(Date:3/31/2015)... NC (PRWEB) March 31, 2015 Smartlink ... engagement technology, today announced that Chris Lynch, Managing ... Annual Southeast Venture Conference (SEVC) this week in Charlotte, ... technology firms in the southeast region and provides these ... capitalists and private equity investors. , This year’s ...
(Date:3/31/2015)... and Willimantic, CT (PRWEB) March 31, 2015 ... word about the settlement of a nationwide class ... 5:11-CV-17, District of Vermont) and seeking to end ... patients who did not meet an “improvement standard”, ... Advocacy are releasing a video conversation with Ali ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 2Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 3Health News:CirugiaPlastica-Mexico.net Offering More Expertise in Plastic Surgery with the Addition of New Providers 2Health News:CirugiaPlastica-Mexico.net Offering More Expertise in Plastic Surgery with the Addition of New Providers 3Health News:CirugiaPlastica-Mexico.net Offering More Expertise in Plastic Surgery with the Addition of New Providers 4Health News:Upcoming Survivor Spin Relay Fundraiser Hopes to Raise Thousands of Dollars for Cancer Patients 2Health News:Upcoming Survivor Spin Relay Fundraiser Hopes to Raise Thousands of Dollars for Cancer Patients 3Health News:Smartlink Mobile Chosen to Present at Southeast Venture Conference 2Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 2Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 3Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 4
... screening rates but one that can be fixed, study ... doctor-patient communication and not having a regular primary-care doctor ... rates among black Americans, a new study suggests. , ... Baltimore, and found that those who,d been screened for ...
... may live longer, study suggests, , , MONDAY, April 20 (HealthDay News) ... and know how to manage your stress. , A new study ... people who lived to 100, and longevity is thought to run ... really important traits that set the children of centenarians apart from ...
... Guidance, Now Estimated to be at least $0.35 per ... Providence Service Corporation (Nasdaq: PRSC ) today ... is scheduled to present an overview of the Company,s ... Tuesday, April 21, 2009 at The Waldorf-Astoria Hotel in ...
... U.S. announced today that Apidra(R) SoloSTAR(R) (insulin glulisine ... the rapid-acting insulin analog Apidra(R), is now available ... improve glycemic control in adults and children (4 ... adults with type 2 diabetes. "Sanofi-aventis is committed ...
... April 20 "With Hurricanes Katrina, Rita and ... their physicians and healthcare providers navigate through chaos ... states Al Davies, M.D., a seasoned critical care ... unique solutions which enable communication between patients, their ...
... WASHINGTON, April 20 Today, the Social Security Institute ... a full-scale effort to stop the raid on Social ... bail out banks and insurance companies and prevent Congress ... it over to the government to run. The ...
Cached Medicine News:Health News:Doctor-Patient Talks Key to Blacks Getting Cancer Screens 2Health News:Outgoing Nature Could Get You to 100 2Health News:Outgoing Nature Could Get You to 100 3Health News:Providence Service Corporation to Present at the CIT 4th Annual Healthcare Conference on April 21 2Health News:Providence Service Corporation to Present at the CIT 4th Annual Healthcare Conference on April 21 3Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 2Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 3Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 4Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 5Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 6Health News:Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States 7Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 4Health News:The Social Security Institute Launches Web Site, Inaugurates Campaign to Prevent Nationalization of Healthcare 2
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Gerl tying forceps, titanium, with 0.12 mm teeth....
Microsurgical curved forceps made of titanium has curved shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: